Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Japanese patients with systemic juvenile idiopathic arthritis
2018-002355-15Phase 3
- Sponsor
- Novartis
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by Novartis. Primary endpoint: Proportion achieving adapted ACR Pediatric 30 at Week 8.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on 2018-002355-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002355-15.